Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Chances are, you haven’t heard of metabolic dysfunction–associated steatohepatitis (MASH)—but you’ve almost definitely heard ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

HealthDay News — For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study ...

Once hailed primarily as a diabetes drug and later catapulted into stardom for its weight-loss benefits, Ozempic (semaglutide ...

Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

The reserarchers found that a weekly dose of semaglutide was effective at treating Metabolic Dysfunction-Associated ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

The global race for weight loss solutions has firmly arrived in India—bringing with it hope, hype, and a host of unanswered ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...